UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000005342 |
|---|---|
| Receipt number | R000006306 |
| Scientific Title | Randomized phase II trial of CODE or amrubicin and cisplatin chemotherapy following concurrent cisplatin, etoposide and accelerated hyperfractionation thoracic radiotherapy for limited disease small cell lung cancer (JCOG1011, LD-SCLC/CODE vs AP) |
| Date of disclosure of the study information | 2011/03/30 |
| Last modified on | 2022/08/30 16:12:45 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Randomized phase II trial of CODE or amrubicin and cisplatin chemotherapy following concurrent cisplatin, etoposide and accelerated hyperfractionation thoracic radiotherapy for limited disease small cell lung cancer (JCOG1011, LD-SCLC/CODE vs AP)
Acronym
Randomized phase II trial of CODE or amrubicin and cisplatin chemotherapy following concurrent cisplatin, etoposide and accelerated hyperfractionation thoracic radiotherapy for limited disease small cell lung cancer (JCOG1011, LD-SCLC/CODE vs AP)
Scientific Title
Randomized phase II trial of CODE or amrubicin and cisplatin chemotherapy following concurrent cisplatin, etoposide and accelerated hyperfractionation thoracic radiotherapy for limited disease small cell lung cancer (JCOG1011, LD-SCLC/CODE vs AP)
Scientific Title:Acronym
Randomized phase II trial of CODE or amrubicin and cisplatin chemotherapy following concurrent cisplatin, etoposide and accelerated hyperfractionation thoracic radiotherapy for limited disease small cell lung cancer (JCOG1011, LD-SCLC/CODE vs AP)
Region
| Japan |
Condition
Condition
limited disease small cell lung cancer
Classification by specialty
| Pneumology | Hematology and clinical oncology | Radiology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To evaluate efficacy and safety of CODE or 'Amrubicin plus cisplatin' chemotherapy following concurrent cisplatin, etoposide and accelerated hyperfractionation thoracic radiotherapy, and to select the promising arm for subsequent phase III trials
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Developmental phase
Phase II
Assessment
Primary outcomes
Progression-free survival rate at one-year from 2nd registration
Key secondary outcomes
Response rate, complete response rate, overall survival , progression-free survival , and incidences of adverse event, grade 4 non-hematological toxicit, early death, and treatment-related death
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
NO
Dynamic allocation
YES
Institution consideration
Institution is considered as adjustment factor in dynamic allocation.
Blocking
NO
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
A: etoposide 100mg/m2 days 1-3, cisplatin 80mg/m2 day 1, and thoracic radiotherapy 45Gy/30 fractions, followed by three cycles of cisplatin 25mg/m2 days 1, 8, vincristine 1mg/m2 day 8, doxorubicin 40mg/m2 day 1, and etoposide 80mg/m2 days 1-3. Prophylactic cranial irradiation 25Gy/10 fractions for patients with CR.
Interventions/Control_2
B: etoposide 100mg/m2 days 1-3, cisplatin 80mg/m2 day 1, and thoracic radiotherapy 45Gy/30 fractions, followed by three cycles of cisplatin 60mg/m2 day 1, and amrubicin 40mg/m2 days 1-3. Prophylactic cranial irradiation 25Gy/10 fractions for patients with CR.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 70 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1) a histological or cytological diagnosis of small cell lung cancer
2) limited disease and clinical stage II-III
3) age between 20 and 70 years old
4) ECOG performance status of 0-1
5) having a measurable disease
6) the first treatment for small cell lung cancer
7) no prior chemothearpy or thoracic radiotherapy for any malignancies
8) a radiation oncologist determines that radiothearpy is possible
9 ) adequate organ functions defined as indicated below;
i) WBC of 4,000/mm3 or more
ii) Hemoglobin of 9.0 g/dL or more
iii) Platelet of 100,000/mm3 or more
iv) Total serum bilirubin of 1.5 mg/dL or less
v) GOT (AST) of 100 IU/L or less
vi) GPT (ALT) of 100 IU/L or less
vii) Serum creatinine of 1.3 mg/dL or less
viii) PaO2 of 70 torr or more at room air
10) written informed consent
Key exclusion criteria
1) synchronous or metachronous active malignancies
2) allergy to a contrast agent
3) any of the followings:
i) inappropriate secretion of antidiuretic hormone (SIADH)
ii) ectopic ACTH syndrome
iii) Lambert-Eaton myasthenic syndrome
iv) subacute cerebellar degeneration
v) paraneoplastic encephalomyelitis / sensory neuropathy
4) infection requiring systemic treatment
5) fever of 38 degrees centigrade or higher within 24 hours before registration
6) pregnant or lactating women
7) psychotic disorder
8) receiving systemic steroid therapy
9) unstable angina or myocardial infarction within the past 6 months
10) uncontrolled hypertension
11) uncontrolled diabetes mellitus or administration of insulin
12) interstitial pneumonitis or lung fibrosis identified by a chest X-ray, or severe pulmonary emphysema
Target sample size
80
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Tomohide Tamura |
Organization
National Cancer Center Hospital
Division name
Division of Thoracic Oncology
Zip code
Address
Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan
TEL
03-3542-2511
JCOG_sir@ml.jcog.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Ikuo Sekine |
Organization
JCOG1011 Coordinating Office
Division name
Division of Thoracic Oncology, National Cancer Center Hospital
Zip code
Address
Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan
TEL
03-3542-2511
Homepage URL
http://www.jcog.jp/
JCOG_sir@ml.jcog.jp
Sponsor or person
Institute
Japan Clinical Oncology Group (JCOG)
Institute
Department
Personal name
Funding Source
Organization
Ministry of Health, Labour and Welfare
Organization
Division
Category of Funding Organization
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
国立病院機構旭川医療センター（北海道）
国立病院機構北海道がんセンター（北海道）
宮城県立がんセンター（宮城県）
山形県立中央病院（山形県）
茨城県立中央病院・茨城県地域がんセンター（茨城県）
栃木県立がんセンター（栃木県）
国立病院機構西群馬病院（群馬県）
群馬県立がんセンター（群馬県）
埼玉県立がんセンター（埼玉県）
国立がん研究センター東病院（千葉県）
国立がん研究センター中央病院（東京都）
がん・感染症センター都立駒込病院（東京都）
国立国際医療研究センター病院（東京都）
がん研究会有明病院（東京都）
順天堂大学医学部附属順天堂医院（東京都）
神奈川県立病院機構神奈川県立がんセンター（神奈川県）
横浜市立市民病院（神奈川県）
新潟県立がんセンター新潟病院（新潟県）
岐阜市民病院（岐阜県）
静岡県立静岡がんセンター（静岡県）
愛知県がんセンター中央病院（愛知県）
国立病院機構名古屋医療センター（愛知県）
愛知県がんセンター愛知病院（愛知県）
大阪市立大学医学部附属病院（大阪府）
近畿大学医学部（大阪府）
大阪府立病院機構大阪府立成人病センター（大阪府）
大阪市立総合医療センター（大阪府）
兵庫県立がんセンター（兵庫県）
倉敷中央病院（岡山県）
岡山大学病院（岡山県）
国立病院機構山口宇部医療センター（山口県）
国立病院機構四国がんセンター（愛媛県）
国立病院機構九州がんセンター（福岡県）
熊本地域医療センター（熊本県）
Other administrative information
Date of disclosure of the study information
| 2011 | Year | 03 | Month | 30 | Day |
Related information
URL releasing protocol
Publication of results
Published
Result
URL related to results and publications
https://www.ncbi.nlm.nih.gov/pubmed/28625642
Number of participants that the trial has enrolled
Results
See the datails via "URL releasing results" above.
Also the details can be seen in the JCOG website:
http://www.jcog.jp/en/trials/index.html
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2011 | Year | 03 | Month | 02 | Day |
Date of IRB
| 2011 | Year | 03 | Month | 18 | Day |
Anticipated trial start date
| 2011 | Year | 03 | Month | 30 | Day |
Last follow-up date
| 2017 | Year | 09 | Month | 01 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2011 | Year | 03 | Month | 30 | Day |
Last modified on
| 2022 | Year | 08 | Month | 30 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006306
